Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Operating activities
Net income (loss)	$ (260,017)	$ (164,281)
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation and amortization	6,534	6,056
Non-cash operating lease cost	2,176	1,492
Non-cash interest expense and amortization of debt issuance costs	4,892	4,010
Payment on notes attributed to accreted interest related to the debt discounts	(22,057)	(10,783)
Acquired in-process research and development	12,271	12,524
Stock-based compensation	39,116	46,406
Loss on debt extinguishment	5,732	6,695
Gain on derivative liabilities	(4,800)	(1,900)
Loss on marketable investments	26,958	(30,530)
Loss on equity method investments	59	441
Gain (loss) on contingent consideration	(66,400)	100
Loss on impairment of intangible assets	90,780
Deferred income taxes	(671)	(916)
Changes in operating assets and liabilities, excluding effect of acquisitions:
Accounts receivable	(2,389)	(1,429)
Inventory	(11,375)	(2,684)
Accrued payroll	6,989	(2,503)
Prepaid expenses, deposits and other assets	4,280	662
Accounts payable	1,427	2,936
Accrued expenses and other liabilities	3,976	5,739
Deferred revenue	(1,587)	776
Other	(242)	617
Net cash used for operating activities	(164,348)	(126,572)
Investing activities
Proceeds from sale of marketable investment		95,171
Purchases of property and equipment	(5,298)	(5,487)
Net cash (used for) provided by investing activities	(15,392)	76,656
Financing activities
Proceeds from short-term debt, net of issuance costs	57,093	22,456
Proceeds from exercise of stock options and warrants	805	11,974
Repayments of debt and other obligations	(111,339)	(56,976)
Net cash provided by financing activities	215,140	70,415
Net change in cash, cash equivalents and restricted cash	35,400	20,499
Net effect of exchange rate changes on cash	(1,720)	328
Cash, cash equivalents and restricted cash at beginning of period	36,665	56,464
Cash, cash equivalents and restricted cash at end of period	70,345	77,291
Cash paid during the period for:
Interest	234	88
Income Taxes	(31)
Supplemental disclosures of non-cash investing and financing activities:
Changes to noncontrolling interests from increased ownership in Scilex Holding		23,963
ACEA acquisition consideration paid in equity		42,168
Virex Health acquisition consideration paid in equity	4,435
Deferred consideration for intangible asset acquisition	3,650
Other acquisitions, license agreements and investments paid in equity		12,877
Property and equipment costs incurred but not paid	950	808
Non-cash additions related to leasehold improvements		2,963
Short-term debt		7,304
ACEA Therapeutics, Inc
Investing activities
Acquisition consideration paid in cash, net of cash acquired		(754)
Virex Health, Inc
Investing activities
Acquisition consideration paid in cash, net of cash acquired	(6,544)
Other Acquisitions and Investments
Investing activities
Acquisition consideration paid in cash, net of cash acquired	(3,550)	(12,274)
Public Offering Of Common Stock And Warrants 2019
Financing activities
Proceeds from equity offerings, net of issuance costs	$ 268,581	$ 92,961